貨號：GS40072

Bempikibart (also known as ADX-914) is a fully human monoclonal antibody designed to act as an antagonist by selectively targeting the Interleukin-7 receptor alpha subunit (IL-7Ralpha). Its mechanism is unique as the IL-7Ralpha subunit is a shared component of two distinct, critical signaling pathways: those driven by Interleukin-7 (IL-7) and Thymic Stromal Lymphopoietin (TSLP). By binding to and blocking IL-7Ralpha, Bempikibart achieves simultaneous inhibition of both the IL-7 and TSLP signaling pathways. This dual blockade is intended to suppress the pathogenic activity of various T-helper cell subtypes (Th1 and Th2) and related downstream inflammation.